Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome.
Standard
Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. / Kröger, Nicolaus.
In: BLOOD, Vol. 119, No. 24, 24, 2012, p. 5632-5639.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome.
AU - Kröger, Nicolaus
PY - 2012
Y1 - 2012
N2 - Allogeneic hematopoietic stem cell transplantation (SCT) is well accepted as a curative treatment approach for younger patients with myelodysplastic syndrome (MDS) and has become one of the most frequent indications for allogeneic SCT as reported to the Center for International Blood and Marrow Transplant Research. However, MDS patients are usually elderly with a median age of approximately 75 years at diagnosis. Large register studies have confirmed the feasibility of the procedure in elderly MDS patients; and in the register of the European Group for Blood and Marrow Transplantation, one-third of the allogeneic transplant procedures for MDS were performed in 2010 in patients older than 60 years. Despite its curative potential, its role in the treatment of elderly MDS patients is less defined. Because of the inherent complications of the transplantation leading to treatment-related mortality and the risk of relapse, a careful calculation of the benefit for each patient is mandatory, taking into account comorbidities, disease status, donor selection, and effective nontransplant therapies. Prospective multicenter studies are needed to define optimal intensity of the conditioning regimen, timing of transplantation within a treatment algorithm, including drug-based therapies, and posttransplant strategies to reduce the risk of relapse.
AB - Allogeneic hematopoietic stem cell transplantation (SCT) is well accepted as a curative treatment approach for younger patients with myelodysplastic syndrome (MDS) and has become one of the most frequent indications for allogeneic SCT as reported to the Center for International Blood and Marrow Transplant Research. However, MDS patients are usually elderly with a median age of approximately 75 years at diagnosis. Large register studies have confirmed the feasibility of the procedure in elderly MDS patients; and in the register of the European Group for Blood and Marrow Transplantation, one-third of the allogeneic transplant procedures for MDS were performed in 2010 in patients older than 60 years. Despite its curative potential, its role in the treatment of elderly MDS patients is less defined. Because of the inherent complications of the transplantation leading to treatment-related mortality and the risk of relapse, a careful calculation of the benefit for each patient is mandatory, taking into account comorbidities, disease status, donor selection, and effective nontransplant therapies. Prospective multicenter studies are needed to define optimal intensity of the conditioning regimen, timing of transplantation within a treatment algorithm, including drug-based therapies, and posttransplant strategies to reduce the risk of relapse.
KW - Humans
KW - Aged
KW - Treatment Outcome
KW - Transplantation, Homologous
KW - Stem Cell Transplantation
KW - Transplantation Conditioning
KW - Iron Overload/complications
KW - Myelodysplastic Syndromes/complications/genetics/therapy
KW - Humans
KW - Aged
KW - Treatment Outcome
KW - Transplantation, Homologous
KW - Stem Cell Transplantation
KW - Transplantation Conditioning
KW - Iron Overload/complications
KW - Myelodysplastic Syndromes/complications/genetics/therapy
U2 - 10.1182/blood-2011-12-380162
DO - 10.1182/blood-2011-12-380162
M3 - SCORING: Journal article
C2 - 22504927
VL - 119
SP - 5632
EP - 5639
JO - BLOOD
JF - BLOOD
SN - 0006-4971
IS - 24
M1 - 24
ER -